Newsroom | 5407 results

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a virtual fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Conference, taking place June 16-17, 2025. Mr. Drysdale’...

SAN FRANCISCO--(BUSINESS WIRE)--SoundHealth, a medical technology company harnessing the power of artificial intelligence and medical science to improve patient outcomes, announced it received United States Food and Drug Administration (FDA) approval for pediatric use of its groundbreaking SONU Band. SONU is the world’s first FDA De Novo authorized, AI-enabled, wearable medical device for at-home treatment of moderate to severe nasal congestion due to allergic and non-allergic rhinitis. This ex...

NEW YORK--(BUSINESS WIRE)--Wisp, the largest pure play women's telehealth company in the U.S. focused on providing sexual and reproductive health solutions to more than 1.5 million customers, today announced the appointment of Jennifer Peña, MD, as the company’s Chief Medical Officer. Dr. Peña will have a crucial role in driving Wisp’s commitment to being the one-stop-shop for all women’s health needs, as the company continues to scale new and existing offerings. As CMO, Dr. Peña will spearhead...

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, shares positive results from a clinical study published in the peer-reviewed journal Aging Cell, by a team led by Masaya Koshizaka, M.D., Ph.D., Associate Professor, and Koutaro Yokote, M.D., Ph.D., MBA, President of Chiba University, both of the Center for Preventive Medical Sciences, Chib...

COLUMBUS, Ohio--(BUSINESS WIRE)--AndHealth Dermatology has welcomed Dr. Drew Kurtzman to its practice starting in May 2025. Dr. Kurtzman is a renowned board-certified dermatologist from Kentucky who will now see patients in Kentucky and Ohio as a part of AndHealth Dermatology. Appointments can be scheduled by calling 614-398-0582, by emailing appointments@andhealth.com, or by visiting DrDrewKurtzmanDermatologist.com. Dr. Kurtzman brings a deep commitment to providing compassionate, expert care...

CHELMSFORD, Mass.--(BUSINESS WIRE)--The Cannabist Company Holdings Inc. (Cboe CA: CBST) (OTCQB: CBSTF) (“The Cannabist Company” or the “Company”), one of the most experienced cultivators, manufacturers and retailers of cannabis products in the U.S., is pleased to announce the appointment of independent directors, Tom Lynch and Peter Lee, to its Board of Directors effective today, in accordance with the terms of the Amended and Restated Indenture dated May 29, 2025, entered into in connection wi...

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, will participate in Oppenheimer’s 25th Annual Consumer Growth and E-Commerce Conference. Mr. Fried is scheduled to participate in a fireside chat on Monday, Jun 9, from 2:15 p.m. to 2:50 p....

LAUSANNE, Switzerland & SAN DIEGO--(BUSINESS WIRE)--HAYA Therapeutics Moves San Diego Operations to Lilly Gateway Labs® to Accelerate Development of RNA-Guided Therapeutics Platform...

HOUSTON--(BUSINESS WIRE)--Rimkus, a premier global provider of engineering, technical consulting, and life sciences services, announced today the strategic acquisition of Huntley-Fenner Advisors Inc., led by Dr. Gavin Huntley-Fenner. The move is an expansion of the Rimkus Life Sciences group with nationally recognized talent, bringing three well recognized and highly skilled human factors experts to the Company’s Life Sciences team. Dr. Huntley-Fenner, a renowned Human Factors leader, brings a...

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that the United States Patent and Trademark Office has granted U.S. patent 12,318,477 in support of its CYB004 deuterated DMT program in development for the treatment of generalized anxiety disorder (“GAD”). The p...